This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, F. Articles by Yu, Y. Search for Related Content PubMed PubMed Citation Articles by Xu, F. Articles by Yu, Y.

The Human ARHI Tumor Suppressor Gene Inhibits Lactation and Growth in Transgenic Mice¹

Departments of Experimental Therapeutics [F. X., R. Z. L., H. P., J. D., Y. L., R. C. B., Y. Y.] and Molecular & Cellular Oncology [W. X., M-C. H.], Division of Pathology and Laboratory Medicine [J. L.], University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030; Departments of Cell Biology [S. Z.] and Neurology [L. Z., W. L.], Baylor College of Medicine, Houston, Texas 77030; and National Hormone and Pituitary Program, Harbor-UCLA Medical Center, Torrance, California 90509 [A. F. P.]

ARHI is a novel imprinted tumor suppressor gene. To study its function in vivo, we have developed transgenic mice that overexpress ARHI. Offspring bearing the transgene had significantly lower body weights than did nontransgenic littermates. In addition, strong expression of the ARHI transgene was associated with greatly impaired mammary gland development and lactation, failure of ovarian folliculogenesis resulting in decreased fertility, loss of neurons in the cerebellar cortex, and impaired development of the thymus. Decrease in body size and defects in the mammary glands correlated with the level of transgene expression. Immunohistochemical analysis indicated that expression of prolactin (PRL), but not growth hormone, was lower in the pituitary glands of mice with defective mammary gland development. The defect in pregnancy-associated mammary tissue proliferation was associated with decreased serum PRL and progesterone levels. Moreover, lower levels of estrogen receptor and progesterone receptor were observed in postpartum mammary glands and in the ovaries of mice that overexpressed ARHI. Our data suggest that ARHI can inhibit PRL secretion and act as a negative regulator in murine growth and development.

This article has been cited by other articles:

				Z. Lu, R. Z. Luo, H. Peng, D. G. Rosen, E. N. Atkinson, C. Warneke, M. Huang, A. Nishmoto, J. Liu, W. S-L. Liao, et al. Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2404 - 2413. [Abstract] [Full Text] [PDF]

				C. D. Hough, K. R. Cho, A. B. Zonderman, D. R. Schwartz, and P. J. Morin Coordinately Up-Regulated Genes in Ovarian Cancer Cancer Res., May 1, 2001; 61(10): 3869 - 3876. [Abstract] [Full Text]